Active immunotherapy for the treatment of cocaine dependence

Drugs of the Future

Volumn 35, Issue 4, 2010, Pages 301-306

  Kinsey, B M ^a   Orson, Frank M ^a   Kosten, T R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN B SUBUNIT; COCAINE; ILLICIT DRUG; MONOCLONAL ANTIBODY; NORCOCAINE; TA CD VACCINE; UNCLASSIFIED DRUG; VACCINE;

ABSENCE OF SIDE EFFECTS; ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIBODY TITER; COCAINE DEPENDENCE; DRUG MECHANISM; DRUG SAFETY; HUMAN; NONHUMAN; REVIEW;

EID: 77954566583     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.04.1474292     Document Type: Review

References (51)

1. History of Cocaine [online]. Available at: http://www.a1b2c3.com/ drugs/coc01.htm.
2. Ruetsch, Y.A., Boni, T., Borgeat, A. From cocaine to ropivacaine: The history of local anesthetic drugs. Curr Top Med Chem 2001, 1(3): 175-82.
3. Gootenberg, P. Andean Cocaine: The Making of a Global Drug. Chapel Hill, NC: University of North Carolina Press, 2008.
4. Drug Related Crime [online]. Available at: http://www.whitehousedrug- policy.gov/publications/factsht/crime/index.html.
5. Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08- 4343). Rockville, MD. [online]. Available at: http://oas.samhsa.gov.
6. Goldstein, R.A., DesLauriers, C., Burda, A., Johnson-Arbor, K. Cocaine: History, social implications, and toxicity: A review. Semin Diagn Pathol 2009, 26(1): 10-7.
7. Bressan, R.A., Crippa, J.A. The role of dopamine in reward and pleasure behaviour - Review of data from preclinical research. Acta Psychiatr Scand Suppl 2005, (427): 14-21.
8. Thanos, P.K., Michaelides, M., Benveniste, H., Wang, G.J., Volkow, N.D. The effects of cocaine on regional brain glucose metabolism is attenuated in dopamine transporter knockout mice. Synapse 2008, 62(5):319-24.
9. Thanos, P.K., Michaelides, M., Umegaki, H., Volkow, N.D. D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats. Synapse 2008, 62(7): 481-6.
10. Li, M.D., Burmeister, M. New insights into the genetics of addiction. Nat Rev Genet 2009, 10(4): 225-31.
11. Thanos, P.K., Habibi, R., Michaelides, M. et al. Dopamine D4 receptor (D4R) deletion in mice does not affect operant responding for food or cocaine. Behav Brain Res 2010, 207(2): 508-11.
12. Preti, A. New developments in the pharmacotherapy of cocaine abuse. Addict Biol 2007, 12(2): 133-51.
13. Berzofsky, J.A., Berkower, I.J. (Eds.) Immunogenicity and Antigen Structure, 2nd Ed. New York: Raven Press, 1989.
14. Bagasra, O., Forman, L.J., Howeedy, A., Whittle, P. A potential vaccine for cocaine abuse prophylaxis. Immunopharmacology 1992, 23(3): 173-9.
15. Gallacher, G. A potential vaccine for cocaine abuse prophylaxis? Immunopharmacology 1994, 27(1): 79-84.
16. Chandrakumar, N.S., Carron, C.P., Meyer, D.M., Beardsley, P.M., Nash, S.A., Tam, L.L., Rafferty, M. Phenylphosphonate monoester analogs of cocaine. Potential haptens for the generation of catalytic antibodies. Bioorg Med Chem Lett 1993, 3(2): 309-12.
17. Landry, D.W., Zhao, K., Yang, G.X., Glickman, M., Georgiadis, T.M. Antibody-catalyzed degradation of cocaine. Science 1993, 259(5103): 1899-901.
18. Basmadjian, G.P., Singh, S., Sastrodjojo, B. et al. Generation of polyclonal catalytic antibodies against cocaine using transition state analogs of cocaine conjugated to diphtheria toxoid. Chem Pharm Bull (Tokyo) 1995, 43(11): 1902-11.
19. Yang, G.X., Chun, J., Arakawa-Uramoto, H., Wang, X., Gawinowcz, M.A., Zhao, K., Landry, D.W. Anti-cocaine catalytic antibodies: A synthetic approach to improved antibody diversity. J Am Chem Soc 1996, 118(25): 5881-90. (Pubitemid 26236808)
20. McKenzie, K.M., Mee, J.M., Rogers, C.J., Hixon, M.S., Kaufmann, C.F., Janda, K.D. Identification and characterization of single chain anti-cocaine catalytic antibodies. J Mol Biol 2007, 365(3): 722-31.
21. Carrera, M.R., Ashley, J.A., Parsons, L.H., Wirsching, P., Koob, G.F., Janda, K.D. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995, 378(6558): 727-30. (Pubitemid 26001945)
22. Carrera, M.R., Ashley, J.A., Zhou, B., Wirsching, P., Koob, G.F., Janda, K.D. Cocaine vaccines: Antibody protection against relapse in a rat model. Proc Natl Acad Sci U S A 2000, 97(11): 6202-6.
23. Carrera, M.R., Trigo, J.M., Wirsching, P., Roberts, A.J., Janda, K.D. Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav 2005, 81(4): 709-14.
24. Redwan el, R.M., Larsen, N.A., Zhou, B., Wirsching, P., Janda, K.D., Wilson, I.A. Expression and characterization of a humanized cocaine-binding antibody. Biotechnol Bioeng 2003, 82(5): 612-8.
25. Larsen, N.A., Zhou, B., Heine, A., Wirsching, P., Janda, K.D., Wilson, I.A. Crystal structure of a cocaine-binding antibody. J Mol Biol 2001, 311(1): 9-15.
26. Sakurai, M., Wirsching, P., Janda, K.D. Design and synthesis of a cocaine- diamide hapten for vaccine development. Tetrahedron Lett 1996, 37(31): 5479-82. (Pubitemid 26241065)
27. Carrera, M.R., Ashley, J.A., Wirsching, P., Koob, G.F., Janda, K.D. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci U S A 2001, 98(4): 1988-92. (Pubitemid 32165610)
28. Ino, A., Dickerson, T.J., Janda, K.D. Positional linker effects in haptens for cocaine immunopharmacotherapy. Bioorg Med Chem Lett 2007, 17(15): 4280-3.
29. Ettinger, R.H., Ettinger, W.F., Harless, W.E. Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol Biochem Behav 1997, 58(1): 215-20.
30. Johnson, M.W., Ettinger, R.H. Active cocaine immunization attenuates the discriminative properties of cocaine. Exp Clin Psychopharmacol 2000, 8(2): 163-7.
31. Orson, F.M., Kinsey, B.M., Singh, R.A., Wu, Y., Kosten, T.R. Vaccines for cocaine abuse. Hum Vaccin 2009, 5(4): 194-9.
32. Hrafnkelsdottir, K., Valgeirsson, J., Gizurarson, S. Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant. Biol Pharm Bull 2005, 28(6): 1038-42. (Pubitemid 40880311)
33. Danger, Y., Devys, A., Gadjou, C., Galons, H., Blanchard, D., Follea, G. Development of monoclonal antibodies directed against cocaine and cocaethylene: Potential new tools for immunotherapy. Hybrid Hybridomics 2004, 23(4): 212-8.
34. Gadjou, C., Danger, Y., Sandouka, P., Scherrmann, J.-M., Blanchard, D., Follea, G., Galons, H. Design of cocaethylene and cocaine conjugates to produce highly selective polyclonal antibodies. Int J Biomed Sci 2006, 2(1): 53-8.
35. Paula, S., Tabet, M.R., Farr, C.D., Norman, A.B., Ball, W.J. Jr. Three-dimensional quantitative structure-activity relationship modeling of cocaine binding by a novel human monoclonal antibody. J Med Chem 2004, 47(1): 133-42. (Pubitemid 38040497)
36. Paula, S., Tabet, M.R., Keenan, S.M., Welsh, W.J., Ball, W.J. Jr. Three- dimensional structure-activity relationship modeling of cocaine binding to two monoclonal antibodies by comparative molecular field analysts. J Mol Biol 2003, 325(3): 515-30. (Pubitemid 36062680)
37. Pozharski, E., Moulin, A., Hewagama, A., Shanafelt, A.B., Petsko, G.A., Ringe, D. Diversity in hapten recognition: Structural study of an anti-cocaine antibody M82G2. J Mol Biol 2005, 349(3): 570-82. (Pubitemid 40724567)
38. Fox, B.S., Kantak, K.M., Edwards, M.A. et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996, 2(10): 1129-32.
39. Kantak, K.M., Collins, S.L., Bond, J., Fox, B.S. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl) 2001, 153(3): 334-40. (Pubitemid 32125818)
40. Kantak, K.M., Collins, S.L., Lipman, E.G., Bond, J., Giovanoni, K., Fox, B.S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self- administration model. Psychopharmacology (Berl) 2000, 148(3): 251-62. (Pubitemid 30136732)
41. Kosten, T.R., Rosen, M., Bond, J. et al. Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine 2002, 20(7-8): 1196-204. (Pubitemid 34135957)
42. Martell, B.A., Mitchell, E., Poling, J., Gonsai, K., Kosten, T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005, 58(2): 158-64. (Pubitemid 41008133)
43. Martell, B.A., Orson, F.M., Poling, J., Mitchell, E., Rossen, R.D., Gardner, T., Kosten, T.R. Cocaine vaccine for the treatment of cocaine dependence: A randomized double-blind placebo-controlled efficacy trial. Arch Gen Psychiatry 2009, 66(10): 1116-23.
44. Jenkins, A.J., Keenan, R.M., Henningfield, J.E., Cone, E.J. Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J Anal Toxicol 2002, 26(7): 382-92.
45. Haney, M., Gunderson, E.W., Jiang, H., Collins, E.D., Foltin, R.W. Cocaine- specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010 67(1): 59-65.
46. Haney, M., Spealman, R. Controversies in translational research: Drug self- administration. Psychopharmacology (Berl) 2008, 199(3): 403-19.
47. Smith, T.W., Skubitz, K.M. Kinetics in interactions between antibodies and haptens. Biochemistry 1975, 14(7): 1496-502.
48. Deliyannis, G., Kedzierska, K., Lau, Y.F., Zeng, W., Turner, S.J., Jackson, D.C., Brown, L.E. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 2006, 36(3): 770-8.
49. Gao, Y., LaFleur, D., Shah, R., Zhao, Q., Singh, M., Brimijoin, S. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: Catalytic and pharmacokinetic properties. Chem Biol Interact 2008, 175(1-3): 83-7.
50. Gao, Y., Brimijoin, S. An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Exp Ther 2004, 310(3): 1046-52.
51. Gao, Y., Orson, F.M., Kinsey, B.M., Kosten, T.R., Brimijoin, S. The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem Biol Interact 2010, Epub ahead of print.